Canadian cannabis stocks remain a bright spot in the cannabis stock market and investors need to focus on leading opportunities to be successful.

From international opportunities to emerging trends like smokeless products, Canadian cannabis producers have capitalizing from several emerging growth trends and we are favorable on this opportunity.

Today, we have highlighted three Canadian marijuana producers that are capitalizing on the global cannabis market and that investors need to be aware of.

Canopy Growth: Growing on a Third Continent

Canopy Growth (WEED.TO) (TWMJF) genetics are growing in soil on its third continent after successfully completing the transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA. The transfer of these plants completes the first phase of a partnership where Alcaliber will be producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy is currently the world’s largest and most diverse licensed medical marijuana producer and has a greater breadth of multi-site management than any other cannabis firm in the world, operating in seven countries internationally and servicing more than 70,000 medical marijuana patients in Canada as of December 31, 2017.

From Denmark to Chile, Australia to Germany, Canopy Growth has become a global cannabis leader. Although the shares have moved considerably higher over the last year, we remain bullish on the long-term outlook. Canopy Growth is capitalizing on a global movement that is barely in the first inning of a multi-decade growth cycle.

Canopy Growth remains one of the best long-term cannabis investment opportunities and is very well capitalized. The cannabis producer has the largest market share of Canada, received a $250 million investment from Constellation Brands (STZ), and continues to increase market share in legal cannabis markets across the globe.

MedReleaf: Enters Germany’s Medical Marijuana Market

MedReleaf Corp. (LEAF.TO) (MEDFF) recorded mixed movements after announcing an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH, a leading medical cannabis distributor to pharmacies in Germany.

MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf's European Medical Agency Good Manufacturing Practices certification and export permit from Health Canada in the coming weeks.

Medical cannabis in Germany has been in short supply and Cannamedical is an ideal partner to bring MedReleaf's premium cannabis products into Germany as one of Europe's leading cannabis distributors with shared values on patient-centricity, a proven track record, and a growing network of 1,800 pharmacies.

We are favorable on this supply agreement and believe it better positions MedReleaf as a global cannabis player. The marijuana producer is well capitalized and well positioned to capitalize on several emerging growth opportunities.

CanniMed: A Burgeoning Cannabis Oils Business

CanniMed Therapeutics Inc. (CMED.TO) (CMMDF) recorded mixed movements after releasing first quarter earnings results and we are favorable on these numbers. When compared to the same period last year, the marijuana producer recorded strong growth and revenue increased by over 40% on a year-over-year basis.

One of the reasons why we were so favorable on the Aurora Cannabis (ACB.TO) (ACBFF) acquisition was due to CanniMed’s focus on smokeless cannabis products. The trend toward smokeless marijuana products continues to increase and CanniMed was an earlier adopter to this. The company was one of the first to receive a license to sell cannabis oils from Health Canada and produces cannabis in a GMP compliant facility.

We are bullish on the company’s cannabis oils business, which continued to become a bigger part of the overall business during the first quarter. In 2017, cannabis oils accounted for approximately 51% of total revenues. During the first quarter, this number increased to 58%. In 2018, we expect this trend to become more pronounced and expect cannabis oils to account for more than 60% of total revenues.

During the quarter, CanniMed launched its Topical Cream, an innovative new product that has been formulated to provide relief from pain and inflammation. The company began fulfilling orders and shipping this product to registered patients during the second quarter. CanniMed is prepared to start selling cannabis oil capsules, in anticipation of Health Canada approval in the second quarter of 2018.

We are favorable on the combined company (Aurora and CanniMed) and will keep an eye on how CanniMed continues to trade ahead of this acquisition closing.